ARTICLE | Clinical News

GS 393 data

December 20, 1993 8:00 AM UTC

Preliminary results of a Phase I/II trial showed that the agent was associated with decreased p24 antigen in blood and transient increases in CD4 counts in patients with advanced AIDS. The changes were not statistically significant.

A total of 28 HIV-positive patients have been treated for up to six months by daily or thrice-weekly intravenous or subcutaneous injections, with 1 or 3 mg/kg doses tested. Dose-limiting toxicity included neutropenia and increased liver enzymes (transaminases). One patient had a transient ulceration of the urethra. ...